Drug major Lupin expects to launch around 30 drugs in the US market in the current fiscal while it is waiting for approval of around 160 products from the USFDA. The Mumbai-based firm confirmed that products filings have been made to the US health regulator from Indian as well as overseas facilities of the Company. Meanwhile, Lupin share price continues with its forward movement. The share price is currently trading at Rs 1,551.85, up by 0.79 per cent.